You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 7, 2024

Netupitant; palonosetron hydrochloride - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic drug sources for netupitant; palonosetron hydrochloride and what is the scope of patent protection?

Netupitant; palonosetron hydrochloride is the generic ingredient in one branded drug marketed by Helsinn Hlthcare and is included in one NDA. There are twelve patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Netupitant; palonosetron hydrochloride has seventy-six patent family members in forty-one countries.

One supplier is listed for this compound.

Summary for netupitant; palonosetron hydrochloride
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for netupitant; palonosetron hydrochloride
Generic Entry Date for netupitant; palonosetron hydrochloride*:
Constraining patent/regulatory exclusivity:
Dosage:
CAPSULE;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for netupitant; palonosetron hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Sichuan Cancer Hospital and Research InstituteN/A
Helsinn Healthcare SAPhase 4
Instituto Brasileiro de Controle do CancerPhase 2

See all netupitant; palonosetron hydrochloride clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for netupitant; palonosetron hydrochloride

US Patents and Regulatory Information for netupitant; palonosetron hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Helsinn Hlthcare AKYNZEO netupitant; palonosetron hydrochloride CAPSULE;ORAL 205718-001 Oct 10, 2014 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Helsinn Hlthcare AKYNZEO netupitant; palonosetron hydrochloride CAPSULE;ORAL 205718-001 Oct 10, 2014 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Helsinn Hlthcare AKYNZEO netupitant; palonosetron hydrochloride CAPSULE;ORAL 205718-001 Oct 10, 2014 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Helsinn Hlthcare AKYNZEO netupitant; palonosetron hydrochloride CAPSULE;ORAL 205718-001 Oct 10, 2014 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Helsinn Hlthcare AKYNZEO netupitant; palonosetron hydrochloride CAPSULE;ORAL 205718-001 Oct 10, 2014 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y Y ⤷  Sign Up
Helsinn Hlthcare AKYNZEO netupitant; palonosetron hydrochloride CAPSULE;ORAL 205718-001 Oct 10, 2014 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for netupitant; palonosetron hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Helsinn Hlthcare AKYNZEO netupitant; palonosetron hydrochloride CAPSULE;ORAL 205718-001 Oct 10, 2014 ⤷  Sign Up ⤷  Sign Up
Helsinn Hlthcare AKYNZEO netupitant; palonosetron hydrochloride CAPSULE;ORAL 205718-001 Oct 10, 2014 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for netupitant; palonosetron hydrochloride

Country Patent Number Title Estimated Expiration
European Patent Office 2727590 Compositions pour traiter les nausées et vomissements à médiation centrale (Compositions for treating centrally mediated nausea and vomiting) ⤷  Sign Up
Ukraine 105817 КОМПОЗИЦИИ ДЛЯ ЛЕЧЕНИЯ ТОШНОТЫ И РВОТЫ ЦЕНТРАЛЬНОГО ПРОИСХОЖДЕНИЯ;КОМПОЗИЦІЇ ДЛЯ ЛІКУВАННЯ НУДОТИ І БЛЮВАННЯ ЦЕНТРАЛЬНОГО ПОХОДЖЕННЯ (Normal;heading 1;heading 2;heading 3;COMPOSITIONS FOR TREATING CENTRALLY MEDIATED NAUSEA AND VOMITING) ⤷  Sign Up
China 102655864 Compositions and methods for treating centrally mediated nausea and vomiting ⤷  Sign Up
Australia 2010320598 Compositions for treating centrally mediated nausea and vomiting ⤷  Sign Up
San Marino T201600427 COMPOSIZIONI PER TRATTARE NAUSEA E VOMITO MEDIATI A LIVELLO CENTRALE ⤷  Sign Up
European Patent Office 2361090 COMPOSITIONS POUR TRAITER LES NAUSÉES ET VOMISSEMENTS À MÉDIATION CENTRALE (COMPOSITIONS FOR TREATING CENTRALLY MEDIATED NAUSEA AND VOMITING) ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for netupitant; palonosetron hydrochloride

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2785706 2090015-5 Sweden ⤷  Sign Up PRODUCT NAME: FOSNETUPITANT; REG. NO/DATE: EU/1/15/1001 20200317
1035115 CR 2015 00044 Denmark ⤷  Sign Up PRODUCT NAME: NETUPITANT; REG. NO/DATE: EU/1/15/1001 20150529
2785706 SPC/GB20/037 United Kingdom ⤷  Sign Up PRODUCT NAME: FOSNETUPITANT; REGISTERED: UK EU/1/15/1001 (NI) 20200318; UK PLGB 12333/0017-0001 20200318
1035115 C01035115/01 Switzerland ⤷  Sign Up PRODUCT NAME: NETUPITANT; REGISTRATION NO/DATE: SWISSMEDIC 65499 06.11.2015
2785706 20C1029 France ⤷  Sign Up PRODUCT NAME: FOSNETUPITANT OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, EN PARTICULIER LE SEL DE CHLORHYDRATE DE CHLORURE DE FOSNETUPITANT; REGISTRATION NO/DATE: EU/1/15/1001 20200318
2785706 C20200029 00371 Estonia ⤷  Sign Up PRODUCT NAME: FOSNETUPITANT;REG NO/DATE: EU/1/15/1001; 18.03.2020
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.